secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001127537-25-000023
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q1 2025 revenue $22.5M (+20% YoY); net loss $14.4M; reaffirms FY guidance
--------------------------------------------------------------------------------

- Worldwide revenue of $22.5M, up 20% YoY (21% constant currency); U.S. $14.2M (+11%), international $8.3M (+39%).
- Net loss $14.4M ($0.36 per share) vs $13.7M ($0.36) in Q1 2024; adjusted EBITDA loss $8.5M vs $8.0M.
- Reaffirms FY2025 revenue guidance $96M-$98M; expects gross margin ~74% and OpEx $133M-$135M.
- U.S. DOJ declined to intervene in case against Pulmonx and closed the civil investigative demand.
- Amended CIBC loan to extend interest-only period through October 2027; cash & securities $88.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753725000023/0001127537-25-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753725000023/lung-20250430.htm
  HTML page:      https://secwatch.observer/filing/0001127537-25-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer